A new #JACC study evaluates repeat rejection after pediatric #Hearttx, finding that while it occurs less often, it remains a risk factor for graft loss. @ToddNeale reports on the findings in @TCTMD: https://t.co/69jkhrGgJW #cvPed
Breast artery calcification is linked with worse CV outcomes in women, according to a new study in #JACCAdvances. Learn more with @TCTMD: https://t.co/gNQRZ13u2n @ToddNeale#CardioX
The #1 reason for GDMT underuse in #HFrEF patients is clinical inertia, according to a research letter in #JACCHF. @ToddNeale discusses the findings in @TCTMD: https://t.co/W2VVO3SDHk
Commenting to @ToddNeale, ACC VP @ChrisKramerMD, said https://t.co/QiUvvuXbfi adds “to the amount of evidence that suggests that one can palliate TR with edge-to-edge repairs and improve QoL and the ability to do activities of daily living." https://t.co/LuordXAaHS #ESCCongress
A new analysis finds renal denervation using radiofrequency energy is cost-effective, high-value intervention for patients with uncontrolled #hypertension. @TCTMD's @ToddNeale reports: https://t.co/iti3zxw30v
ACC has updated its expert consensus decision pathway for patients hospitalized with #HeartFailure. The updated guidance is published in #JACC. Get the details: https://t.co/MkISxoVq6I @TCTMD@ToddNeale
"It adds another layer in us being able to initiate this therapy with a little more precision," @AlexRazavi says; comments from @CardiacCTGuy#SCCT2024 https://t.co/ciaLtrs5ct
"This highlights the critical role of coronary inflammation as a potential therapeutic target in cardiovascular prevention," Kenneth Chan says #SCCT2024; commentary from @ChinnaiyanMD https://t.co/MO0Fn3AW7C
“I think internationally we have a collective responsibility to help this part of the world.”
Prof Craig Anderson talks to @ToddNeale from @TCTMD about the under-representation of Asia-Pacific in cardiovascular clinical trials.
https://t.co/KyurGVF6SE
"Despite the fact that a lion’s share of the burden of disease is going to be where the population is, we don’t tend to perform trials in this region or enroll as many patients from this region," @ProfSNicholls says; @dukwoo_park, Craig Anderson weigh in https://t.co/TxZdYKm7r3
"Some of this, I believe, is a reasonable use, a medically justifiable use. But I do believe that there is definitely a proportion of these patients who do not need to be on a daily preventive aspirin," @MohakGuptaMD says @TCTMD https://t.co/JEZ0SE7xG9
Although there was no significant difference in all-cause mortality between the DOAC and VKA groups at 1 year, a significant difference had emerged by 3 years and widened by 5 years, @AgamBansal5 reports #NYValves2024@JimmyStewart00@TCTMD https://t.co/kSqUmnVXHq